Percentage changes in antiinfluenza immunoglobulin G titers at Week 52 compared with baseline in patients who received influenza vaccination prior to Day 0 who were not revaccinated during the study.
| Standard Therapy + Placebo | Standard Therapy + Belimumab 1 mg/kg | Standard Therapy + Belimumab 10 mg/kg | |
|---|---|---|---|
| Influenza antigens, 2006–7 vaccine, n†† | 16 | 23 | 12 |
| New Caledonia: mean IgG % change in titer at Week 52 (SE) | 31.8 (17.2) | 24.5 (20.3) | 1.2 (19.0) |
| Median | 0.0 | 0.0 | −18.2 |
| Wisconsin: mean IgG % change in titer at Week 52 (SE) | 901.9 (788.1) | 4.8 (16.8)* | −11.4 (12.3)* |
| Median | 0.0 | 0.0 | 0.0 |
| Malaysia: mean IgG % change in titer at Week 52 (SE) | 40.4 (17.5) | −13.0 (7.7)* | 520.8 (525.5) |
| Median | 0.0 | 0.0 | 0.0 |
| Influenza antigens, 2007–8 vaccine, n†† | 29 | 40 | 27 |
| Solomon Island 1,2,3 (n = 39): mean IgG % change in titer at Week 52 (SE) | 2.6 (26.3) | −7.5 (11.2) | −8.7 (16.5) |
| Median | −20.6 | −20.0 | −37.5 |
| Wisconsin 1,2,3 (n = 26): mean IgG % change in titer at Week 52 (SE) | 63.1 (36.9) | 27.1 (20.2) | −4.9 (15.1) |
| Median | 0.0 | 0.0 | −20.6 |
| Malaysia 1,2,3: mean IgG % change in titer at Week 52 (SE) | −7.8 (11.3) | −4.7 (7.6) | −32.0 (5.5) |
| Median | 0.0 | 0.0 | −50.0 |